|
| Title |
Pub. Date |
Int. Class |
App. Num |
Applicant |
| 26. |
(WO 2008/024749) METHODS AND COMPOSITIONS FOR TREATING ISCHEMIC STROKE
|
28.02.2008
|
A61K 31/33
|
PCT/US2007/076381
|
CASE WESTERN RESERVE UNIVERSITY
|
| |
A method of treating a cerebrovascular accident in a subject includes administering a therapeutically effective amount of at least one PPARγ agonist or a derivative thereof to the subject after onset of ischemia sufficient to a cause the cerebrovascular accident and prior to reperfusion.
|
| |
|
| 27. |
(WO 2008/024675) METHOD OF LOCAL DELIVERY OF BIOACTIVE AND DIAGNOSTIC AGENTS USING MAGNETIZABLE BONE CEMENT
|
28.02.2008
|
A61F 2/00
|
PCT/US2007/076126
|
PHILADELPHIA HEALTH & EDUCATION CORPORATION D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE
|
| |
A method of making a magnetizable implant, the method includes mixing a curable matrix and the at least one of the bioactive agent or the diagnostic agent associated with the magnetizable carrier to form a magnetizable curable matrix; implanting the magnetizable curable matrix in a cavity in a body of a mammal whereby the magnetizable curable matrix takes on a shape of the cavity and forms a molded magnetizable curable matrix; simultaneously curing the molded magnetizable curable matrix and applying the magnetic field and thereby causing the at least one of the bioactive agent or the diagnostic agent associated with a magnetizable carrier to move and arrange within the molded magnetizable curable matrix at or near an interface between the c...
|
| |
|
| 28. |
(WO 2008/024663) COMBUSTION KNOCK DETECTION AND CONTROL THROUGH STATISTICAL CHARACTERIZATION OF KNOCK LEVELS
|
28.02.2008
|
G01L 23/22
|
PCT/US2007/076056
|
MICHIGAN TECHNOLOGICAL UNIVERSITY
|
| |
A method of statistically characterizing combustion knock events includes receiving signals from a sensing device such as an accelerometer, estimating at least one parameter of a probability distribution function based on the received signals, and calculating a value indicative of an nth percentile based on the parameter to predict upcoming combustion knock events.
|
| |
|
| 29. |
(WO 2008/024660) METHOD OF REDUCING NEURONAL CELL DAMAGE
|
28.02.2008
|
A01N 43/42
|
PCT/US2007/076034
|
THE UNIVERSITY OF MONTANA
|
| |
The present invention is directed to a method of reducing the occurrence of neuronal cell damage, including death, caused by transient cerebral hypoxia and/or ischemia. The method comprises the steps of: diagnosing a subject having a transient cerebral hypoxic and/or ischemic condition; and within 16 hours after onset of the condition, administering to the subject a neuroprotective amount of a pharmaceutical agent. The pharmaceutical agent is preferably selected from the group consisting of: a central nervous system stimulant (CNSS), monoamine neurotransmitter, monoamine oxidase inhibitor (MAOI), tricyclic antidepressant (TCA), or a combination thereof. Preferred agents include amphetamines, methamphetamine, methylphenidate, methylenedioxym...
|
| |
|
| 30. |
(WO 2008/024642) GENE EXPRESSION SIGNATURES IN BLOOD LEUKOCYTES PERMIT DIFFERENTIAL DIAGNOSIS OF ACUTE INFECTIONS
|
28.02.2008
|
C12Q 1/68
|
PCT/US2007/075713
|
BAYLOR RESEARCH INSTITUTE
|
| |
The present invention includes compositions, systems and methods for the early detection and consistent determination of the extent, type and nature of a host immune response and the nature of the infectious disease using gene expression data.
|
| |
|
| 31. |
(WO 2008/024640) BIODEGRADABLE ELASTOMERIC SCAFFOLDS CONTAINING MICROINTEGRATED CELLS
|
28.02.2008
|
A61F 2/24
|
PCT/US2007/075703
|
COURTNEY, Todd
|
| |
Described herein are elastomeric materials, and in particular porous biodegradable elastomeric materials which optionally may have microintegrated cells. Also described herein are bioprosthetic devices that can be manufactured using the biodegradable elastomeric materials, non-limiting examples of such devices including pulmonary valves, vocal chords, and blood vessels.
|
| |
|
| 32. |
(WO 2008/024623) METHOD AND SOFTWARE TOOL FOR DESIGNING AN INTEGRATED CIRCUIT
|
28.02.2008
|
G06F 17/50
|
PCT/US2007/075443
|
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
|
| |
A method of designing an integrated circuit for an application having standards having a plurality of primitives, each of the primitives having a corresponding response. The method includes generating a macros description of each of the primitives and the response corresponding to each of the primitives, wherein the macros description includes information relating to a number of first fields for each of the primitives and a number of second fields for the response corresponding to each of the primitives. The method further includes receiving a specification of the behavior of the integrated circuit in response to the primitives that has one or more values specified for each of the second fields, and generating a hardware description languag...
|
| |
|
| 33. |
(WO 2008/024575) A CRYOPRESERVATION DEVICE AND METHOD
|
28.02.2008
|
C12N 1/04
|
PCT/US2007/074055
|
THE CURATORS OF THE UNIVERSITY OF MISSOURI
|
| |
A device and method suitable for the cryopreservation of all types of biological cells is described. In this method, an ultra-fast cooling/warming device system is used to achieve vitrification of individual cells or cell suspensions without cryoprotectant agents (CPA) or with a low concentration of CPAs (<1M), to attenuate the formation of intracellular ice crystal formation during cooling, and to minimize devitrification during subsequent warming. The device system applies oscillating heat pipe (OHP) and nanofluid techniques, and is built through microfabrication. Several devices may be networked to increase the total volume of cell samples that the cryopreservation system can process simultaneously.
|
| |
|
| 34. |
(WO 2008/024499) METHODS FOR IN VIVO IDENTIFICATION OF ENDOGENOUS MRNA TARGETS OF MICRORNAS
|
28.02.2008
|
C07H 21/02
|
PCT/US2007/018793
|
DUKE UNIVERSITY
|
| |
A method of generating a gene expression profile of noncoding regulatory RNA (ncRNA; e.g. a microRNA) in a cell in vivo, is carried out by: (a) partitioning from a cell at least one mRNA-protein (RNP) complex, the RNP complex comprising: (i) an RNA binding protein (RNABP) or RNA associated protein, (ii) at least one mRNA bound to or associated with said protein, and (iii) at least one ncRNA bound to or associated with said protein, and then (b) identifying at least one ncRNA in-at least one RNP complex, thereby to produce a gene expression profile comprising the identity of an ncRNA in an RNP complex.
|
| |
|
| 35. |
(WO 2008/024495) BIOMARKERS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION
|
28.02.2008
|
G01N 33/68
|
PCT/US2007/018785
|
UNIVERSITY OF IOWA RESEARCH FOUNDATION
|
| |
The invention relates to proteins associated with age-related macular degeneration (AMD). These proteins, which are present in blood, are expressed in individuals with AMD at either elevated or reduced levels compared to healthy individuals. The invention provides methods for diagnosing AMD. The invention provides methods for assessing the efficacy of treatment of AMD. The invention provides methods for monitoring the progression of AMD.
|
| |
|
| 36. |
(WO 2008/024480) METHOD FOR CLEANING DIFFRACTION GRATINGS
|
28.02.2008
|
G02B 5/18
|
PCT/US2007/018763
|
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
|
| |
A method of cleaning a diffraction grating preferably includes exposing the grating surface to an aqueous base to remove an organic photoresist mask thereon; rinsing the grating surface with de-ionized water; oxidizing acid solution (such as Nanostrip™ or Nanostrip™ 2X) to remove metallic contaminants and residue organic compounds; rinsing the grating surface with de-ionized water; exposing the grating surface to an oxygen plasma ashing process using reactive oxygen species to oxidize and remove fluorinated hydrocarbon residue; exposing the grating surface again to an oxidizing acid solution to remove metallic contaminants and residue organic compounds; and rinsing the grating surface with de-ionized water.
|
| |
|
| 37. |
(WO 2008/024473) MAPPING OF GENOMIC INTERACTIONS
|
28.02.2008
|
C12Q 1/68
|
PCT/US2007/018745
|
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
|
| |
The present invention relates to genomic analysis. In particular, the present invention provides methods and compositions for mapping genomic interactions.
|
| |
|
| 38. |
(WO 2008/024456) SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF
|
28.02.2008
|
A61K 31/167
|
PCT/US2007/018686
|
UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
|
| |
This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, <i>inter alia</i>, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder.
|
| |
|
| 39. |
(WO 2008/024447) DIFFERENTIATION OF PROGENITOR CELLS INTO FIBROBLASTS
|
28.02.2008
|
C12N 5/00
|
PCT/US2007/018670
|
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OFNEW YORK
|
| |
Disclosed herein is a new approach towards differentiation of progenitor cells, for example human mesenchymal cells (hMSCs), into fibroblasts using chemical factors, such as by the treatment of recombinant human connective tissue growth factor (CTGF) and ascorbic acid. One aspect of the invention provides an ex vivo culturing protocol for fibroblastic differentiation of tissue progenitor cells (e.g., human mesenchymal stem cells (hMSCs)) using bioactive factors such as connective tissue growth factor (CTGF). Approaches described herein can provide for significant increases in collagen production from cultured fibroblast progenitor cells.
|
| |
|
| 40. |
(WO 2008/024435) DENDRITIC MOLECULAR INTRACELLULAR TRANSPORTERS AND METHODS OF MAKING AND USING SAME
|
28.02.2008
|
A01N 31/04
|
PCT/US2007/018645
|
VANDERBILT UNIVERSITY
|
| |
In accordance with the purpose(s) of the invention, as embodied and broadly described herein, the invention, in one aspect, relates to compounds comprising the structure: and at least one guanidinium residue, wherein m is zero or a positive integer. Also disclosed are methods of preparing the disclosed compounds. Also disclosed are methods of intracellular delivery comprising administering the disclosed compounds and compositions to a subject. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of one or more compounds or compositions of the invention and a pharmaceutically acceptable carrier. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not inte...
|
| |
|
| 41. |
(WO 2008/024410) OPEN-ENDED CONTROL CIRCUIT FOR ELECTRICAL APPARATUS
|
28.02.2008
|
H02M 5/27
|
PCT/US2007/018587
|
REGENTS OF THE UNIVERSITY OF MINNESOTA
|
| |
An AC machine control system for an AC machine (102) (motor, generator, transformer, etc.) having open-ended windings, the control system comprising a drive circuit (100) configured to transfer AC power between a first set of voltages and each end of the open-ended windings without the use of a substantial energy storage device, while eliminating common mode voltage and/or injecting zero sequence voltages.
|
| |
|
| 42. |
(WO 2008/024409) PROGENITOR CELL REPLICATION AND DIFFERENTIATION IN 3D
|
28.02.2008
|
A01N 63/00
|
PCT/US2007/018586
|
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
|
| |
The present invention is directed to a new approach towards in situ differentiation of tissue progenitor cells, without the conventional requirements of weeks of cellular manipulation and treatment. Such approach circumvents the need for 2D culturing and differentiation of tissue progenitor cells before implanting in a 3D biocompatible matrix, thus providing convenience, cost savings, and time savings. One aspect of the invention provides an engineered tissue composition comprising substantially undifferentiated tissue progenitor cells in a biphasic matrix material, along with growth factors or encapsulated growth factors. Another aspect of the invention includes methods for making the compositions described herein. Another aspect of the in...
|
| |
|
| 43. |
(WO 2008/024363) COPOLYMERIZATION OF PROPYLENE OXIDE AND CARBON DIOXIDE AND HOMOPOLYMERIZATION OF PROPYLENE OXIDE
|
28.02.2008
|
C08F 22/40
|
PCT/US2007/018507
|
CORNELL UNIVERSITY
|
| |
Copolymers of propylene oxide and carbon dioxide and homopolymers of propylene oxide are made using two dimensional double metal cyanide complexes having the formula Co[M(CN)<sb>4</sb>] or hydrated or partially dehydrated form thereof. There is no propylene carbonate by product in the copolymerization.
|
| |
|
| 44. |
(WO 2008/024356) ANIMAL MODEL OF CHOLINERGIC DYSFUNCTION TO EVALUATE COGNITIVE ENHANCERS AND DRUGS THAT IMPROVE MYASTHENIA
|
28.02.2008
|
A01K 67/033
|
PCT/US2007/018499
|
DUKE UNIVERSITY
|
| |
Recombinant non-human mammals having reduced or no expression of vesicular acetylcholine transporter protein (VAChT) as compared to the corresponding wild-type mammal are provided. The mammal may have, <i>e.g.</i>, impaired performance in object and social recognition and/or impaired neuromuscular performance and/or alterations in autonomic nervous system function as compared to the corresponding wild-type mammal. Methods of screening a compound for cholinergic activity or activity in treating a cholinergic neurotransmission disorder are also provided. In addition, a cell such as a nerve cell isolated from a mammal as described herein is provided, along with cell cultures, which are useful <i>in vitro</i...
|
| |
|
| 45. |
(WO 2008/024343) MICRO RNA ARRAYS AND METHODS OF USING THE SAME
|
28.02.2008
|
C12Q 1/68
|
PCT/US2007/018478
|
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
|
| |
Isolated polynucleic acids are disclosed. In some embodiments, the isolated polynucleic acids are selected from the group consisting of (a) a polynucleic acid comprising a nucleic acid sequence set forth in Table 1 or Table 2; (b) a polynucleic acid comprising a nucleic acid sequence having at least about 90% identity to a nucleic acid sequence set forth in Table 1 or Table 2; and (c) a polynucleic acid capable of hybridizing under stringent conditions to a nucleic acid sequence set forth in Table 3 or Table 4, wherein the polynucleic acid is 50 nucleotides or shorter. Also disclosed are libraries of isolated polynucleic acids; kits for determining the presence of miRNA expressed in a sample; methods for detecting, quantifying, or both at l...
|
| |
|
| 46. |
(WO 2008/024318) MULTIPLE FREQUENCY METHOD FOR OPERATING ELECTROCHEMICAL SENSORS
|
28.02.2008
|
G01N 27/407
|
PCT/US2007/018435
|
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
|
| |
A multiple frequency method for the operation of a sensor to measure a parameter of interest using calibration information including the steps of exciting the sensor at a first frequency providing a first sensor response, exciting the sensor at a second frequency providing a second sensor response, using the second sensor response at the second frequency and the calibration information to produce a calculated concentration of the interfering parameters, using the first sensor response at the first frequency, the calculated concentration of the interfering parameters, and the calibration information to measure the parameter of interest.
|
| |
|
| 47. |
(WO 2008/024311) PURIFICATION OF LOW-ABUNDANT RECOMBINANT PROTEINS FROM CELL CULTURE
|
28.02.2008
|
C07K 1/14
|
PCT/US2007/018405
|
DUKE UNIVERSITY
|
| |
A method of purifying a fusion protein from a cell culture containing the same by inverse transition cycling (ITC), said fusion protein comprising a protein or peptide of interest coupled to a bioelastic polymer, is carried out by adding free bioelastic polymer as a co-aggregant to the cell culture solution so that the mass of fusion protein captured from the soluble cell lysate is increased.
|
| |
|
| 48. |
(WO 2008/024300) SEMAPHORIN 7A PLAYS A CRITICAL ROLE IN TGF-β1-INDUCED PULMONARY FIBROSIS AND ALVEOLAR DESTRUCTION
|
28.02.2008
|
A01N 37/18
|
PCT/US2007/018356
|
YALE UNIVERSITY
|
| |
The present invention provides methods of treating a subject diagnosed with, or at risk for developing, pathogenic fibrosis, particularly pulmonary fibrosis. The method of the invention comprises administering to the subject a compound or composition which inhibits semaphorin (SEMA) 7A, SEMA 7A receptors, or downstream effectors. A SEMA 7A inhibitor comprises an antibody, a soluble SEMA 7A receptor, an siRNA, a ribozyme, an antisense, an aptamer, a peptidomimetic, a small molecule, a soluble receptor, or any combinations thereof.
|
| |
|
| 49. |
(WO 2008/024241) CYCLOBUTENE POLYMERS AND METHODS OF MAKING THE SAME
|
28.02.2008
|
C08F 232/08
|
PCT/US2007/018036
|
NORTH CAROLINA STATE UNIVERSITY
|
| |
Described is a cyclobutene polymer comprising: monomeric units of cyclobutene, said cyclobutene having at least one fused ring system substituted thereon, said polymer comprising not more than 10 mol percent ring-opened units of said cyclobutene; and said polymer having a molecular weight of at least 1,000; said polymer optionally copolymerized with a comonomer to form a copolymer therewith. Compositions thereof and methods of making the same are also described.
|
| |
|
| 50. |
(WO 2008/024224) ARTERIOVENOUS GRAFT BLOOD FLOW CONTROLLERS AND METHODS
|
28.02.2008
|
A61M 39/10
|
PCT/US2007/017910
|
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
|
| |
Blood flow restrictors are discussed. In some examples, a restrictor apparatus includes a converging entry portion, a diverging exit portion, and optionally a narrowed portion therebetween to restrict the flow of blood through an arteriovenous graft from a subject's artery to a subject's vein. The structure of the restrictor apparatus decreases the pressure and volume of blood flow between the subject's artery and vein to reduce or prevent hyperplasia or stenosis on the venous side, an increased load on the heart, or blood steal, among other things. The restrictor apparatus can be separate from, but couplable to, the arteriovenous graft. Alternatively, the restrictor apparatus can be integral with the arteriovenous graft. Met...
|
| |
|
![[Back to Top]](/ipdl/include/backtop.gif){kind=small}
